Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from LBT Innovations Limited ( (AU:CC5) ) is now available.
Clever Culture Systems Ltd announced that leading pharmaceutical companies AstraZeneca, Bristol Myers Squibb, and Pfizer will present data on CCS’s APAS® Independence technology at major industry conferences. These presentations will highlight the system’s performance and validation strategies, showcasing its potential as a comprehensive solution for environmental monitoring. The APAS® Independence technology is gaining international recognition, with commitments from major pharmaceutical companies to purchase and standardize its use globally. This development underscores a significant commercial opportunity for CCS, reinforcing its leadership in AI microbiology automation.
More about LBT Innovations Limited
Clever Culture Systems (CCS) is an Adelaide-based company specializing in intelligent automation solutions for microbiology laboratories. The company has developed the Automated Plate Assessment System (APAS® Independence), which uses artificial intelligence and machine learning to automate the imaging, analysis, and interpretation of microbiology culture plates. This technology is the only US FDA-cleared AI technology for automated culture plate reading, targeting microbiology laboratories in the pharmaceutical manufacturing sector for environmental monitoring and clinical laboratories for infectious disease diagnostics.
Average Trading Volume: 2,318,828
Technical Sentiment Signal: Hold
Current Market Cap: A$54.55M
See more insights into CC5 stock on TipRanks’ Stock Analysis page.